FreeCME

New Horizons in Hemophilia: Preparing for the Advent of Gene Therapy

/ Print /
| ShareMore
/ Text Size +
12/10/21 7:00 pm EDT
Hyatt Regency Atlanta + Live Streaming
United States

The New Horizons in Hemophilia: Preparing for the Advent of Gene Therapy is not to be missed!

Hemophilia A occurs in 1 in 5000 live male births and is caused by a mutation in the gene coding for factor VIII (FVIII), resulting in the loss of functional FVIII protein. Treatment of hemophilia requires lifelong use of clotting factor replacement therapy. Recent clinical trial data and ongoing trials are currently investigating novel therapeutic approaches such as gene therapy to improve management of this condition.

Learning Objectives

The learning objectives of this program are:

  • Describe the role of gene therapy for the treatment of hemophilia A and B
  • Evaluate clinical trial findings investigating the role for gene therapy in patients with hemophilia A and B
  • Assess current evidence regarding the relationship between cost-effectiveness data and access barriers for gene therapy
  • Select appropriate therapies for patients with hemophilia based on patient-centered considerations

Date

Friday, December 10, 2021
Registration and Dinner: 6:15 PM – 7:00 PM EST
Scientific Session: 7:00 PM – 9:30 PM EST

 

Location

Hyatt Regency Atlanta
In-person and Live Streaming Satellite Symposium